Pilot evaluation of gabapentin for treating hot flashes

Charles Lawrence Loprinzi, Debra L. Barton, Jeff A Sloan, Katherine M. Zahasky, De Anne R Smith, Sandhya Pruthi, Paul J. Novotny, Edith A. Perez, Bradley J. Christensen

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Objective: To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes. Patients and Methods: This prospective single-arm clinical trial was conducted between July 26, 2001, and November 30, 2001. Patients underwent a baseline week and then 4 weeks of gabapentin treatment, with increasing doses during the first 3 weeks, from 300 to 600 to 900 mg/d. Data were obtained primarily from patient-completed questionnaires. Results: Data from 20 evaluable women (of 24 entered in the trial) were available. Four patients discontinued use of gabapentin for perceived drug-related untoward symptoms, primarily related to light-headedness and dizziness. The 16 patients who completed this clinical trial had a mean reduction in hot flash frequency, in the fourth treatment week compared to the baseline week, of 66%. Their corresponding hot flash score (frequency times average severity) reduction was 70%. Additionally, patients who completed the 4 treatment weeks had a strong tendency to report an improvement in several other symptoms. Conclusion: Although a double-blind placebo-controlled clinical trial should be conducted to better elucidate the efficacy and toxicity of gabapentin in patients with hot flashes, the available data suggest that gabapentin is a reasonable treatment to consider in patients with hot flashes if they do not wish to use hormonal therapy.

Original languageEnglish (US)
Pages (from-to)1159-1163
Number of pages5
JournalMayo Clinic Proceedings
Volume77
Issue number11
StatePublished - Nov 1 2002

Fingerprint

Hot Flashes
Dizziness
Clinical Trials
Therapeutics
gabapentin
Controlled Clinical Trials
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Loprinzi, C. L., Barton, D. L., Sloan, J. A., Zahasky, K. M., Smith, D. A. R., Pruthi, S., ... Christensen, B. J. (2002). Pilot evaluation of gabapentin for treating hot flashes. Mayo Clinic Proceedings, 77(11), 1159-1163.

Pilot evaluation of gabapentin for treating hot flashes. / Loprinzi, Charles Lawrence; Barton, Debra L.; Sloan, Jeff A; Zahasky, Katherine M.; Smith, De Anne R; Pruthi, Sandhya; Novotny, Paul J.; Perez, Edith A.; Christensen, Bradley J.

In: Mayo Clinic Proceedings, Vol. 77, No. 11, 01.11.2002, p. 1159-1163.

Research output: Contribution to journalArticle

Loprinzi, CL, Barton, DL, Sloan, JA, Zahasky, KM, Smith, DAR, Pruthi, S, Novotny, PJ, Perez, EA & Christensen, BJ 2002, 'Pilot evaluation of gabapentin for treating hot flashes', Mayo Clinic Proceedings, vol. 77, no. 11, pp. 1159-1163.
Loprinzi CL, Barton DL, Sloan JA, Zahasky KM, Smith DAR, Pruthi S et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clinic Proceedings. 2002 Nov 1;77(11):1159-1163.
Loprinzi, Charles Lawrence ; Barton, Debra L. ; Sloan, Jeff A ; Zahasky, Katherine M. ; Smith, De Anne R ; Pruthi, Sandhya ; Novotny, Paul J. ; Perez, Edith A. ; Christensen, Bradley J. / Pilot evaluation of gabapentin for treating hot flashes. In: Mayo Clinic Proceedings. 2002 ; Vol. 77, No. 11. pp. 1159-1163.
@article{84de361df9154256be0ae7d15129393d,
title = "Pilot evaluation of gabapentin for treating hot flashes",
abstract = "Objective: To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes. Patients and Methods: This prospective single-arm clinical trial was conducted between July 26, 2001, and November 30, 2001. Patients underwent a baseline week and then 4 weeks of gabapentin treatment, with increasing doses during the first 3 weeks, from 300 to 600 to 900 mg/d. Data were obtained primarily from patient-completed questionnaires. Results: Data from 20 evaluable women (of 24 entered in the trial) were available. Four patients discontinued use of gabapentin for perceived drug-related untoward symptoms, primarily related to light-headedness and dizziness. The 16 patients who completed this clinical trial had a mean reduction in hot flash frequency, in the fourth treatment week compared to the baseline week, of 66{\%}. Their corresponding hot flash score (frequency times average severity) reduction was 70{\%}. Additionally, patients who completed the 4 treatment weeks had a strong tendency to report an improvement in several other symptoms. Conclusion: Although a double-blind placebo-controlled clinical trial should be conducted to better elucidate the efficacy and toxicity of gabapentin in patients with hot flashes, the available data suggest that gabapentin is a reasonable treatment to consider in patients with hot flashes if they do not wish to use hormonal therapy.",
author = "Loprinzi, {Charles Lawrence} and Barton, {Debra L.} and Sloan, {Jeff A} and Zahasky, {Katherine M.} and Smith, {De Anne R} and Sandhya Pruthi and Novotny, {Paul J.} and Perez, {Edith A.} and Christensen, {Bradley J.}",
year = "2002",
month = "11",
day = "1",
language = "English (US)",
volume = "77",
pages = "1159--1163",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Pilot evaluation of gabapentin for treating hot flashes

AU - Loprinzi, Charles Lawrence

AU - Barton, Debra L.

AU - Sloan, Jeff A

AU - Zahasky, Katherine M.

AU - Smith, De Anne R

AU - Pruthi, Sandhya

AU - Novotny, Paul J.

AU - Perez, Edith A.

AU - Christensen, Bradley J.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Objective: To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes. Patients and Methods: This prospective single-arm clinical trial was conducted between July 26, 2001, and November 30, 2001. Patients underwent a baseline week and then 4 weeks of gabapentin treatment, with increasing doses during the first 3 weeks, from 300 to 600 to 900 mg/d. Data were obtained primarily from patient-completed questionnaires. Results: Data from 20 evaluable women (of 24 entered in the trial) were available. Four patients discontinued use of gabapentin for perceived drug-related untoward symptoms, primarily related to light-headedness and dizziness. The 16 patients who completed this clinical trial had a mean reduction in hot flash frequency, in the fourth treatment week compared to the baseline week, of 66%. Their corresponding hot flash score (frequency times average severity) reduction was 70%. Additionally, patients who completed the 4 treatment weeks had a strong tendency to report an improvement in several other symptoms. Conclusion: Although a double-blind placebo-controlled clinical trial should be conducted to better elucidate the efficacy and toxicity of gabapentin in patients with hot flashes, the available data suggest that gabapentin is a reasonable treatment to consider in patients with hot flashes if they do not wish to use hormonal therapy.

AB - Objective: To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes. Patients and Methods: This prospective single-arm clinical trial was conducted between July 26, 2001, and November 30, 2001. Patients underwent a baseline week and then 4 weeks of gabapentin treatment, with increasing doses during the first 3 weeks, from 300 to 600 to 900 mg/d. Data were obtained primarily from patient-completed questionnaires. Results: Data from 20 evaluable women (of 24 entered in the trial) were available. Four patients discontinued use of gabapentin for perceived drug-related untoward symptoms, primarily related to light-headedness and dizziness. The 16 patients who completed this clinical trial had a mean reduction in hot flash frequency, in the fourth treatment week compared to the baseline week, of 66%. Their corresponding hot flash score (frequency times average severity) reduction was 70%. Additionally, patients who completed the 4 treatment weeks had a strong tendency to report an improvement in several other symptoms. Conclusion: Although a double-blind placebo-controlled clinical trial should be conducted to better elucidate the efficacy and toxicity of gabapentin in patients with hot flashes, the available data suggest that gabapentin is a reasonable treatment to consider in patients with hot flashes if they do not wish to use hormonal therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036844441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036844441&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 1159

EP - 1163

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -